Skip to content
KR
EN
Open Whole Menu
About Company
- Overview
- Mission
- Subsidiary
Sustainable management
Financial Highlight
- Financial informationt
PR center
- PR center
Close Whole Menu
HOME > About Company > Subsidiary
SK chemicals
SK gas
SK D&D
SK plasma
SK bioscience
A new challenge for SK plasma to take a leap forward begins.
SK plasma's plasma fractionation business started in 1970 and is being conducted under the mission of SK discovery to 'promote human health and protect the earth's environment'.
In 2015, SK chemicals Life Science biz. was divided and established as a new corporation as we focused on our core competencies in the blood product business to enhance our competitiveness and accelerate global advancement.
Blood products are essential medicines to treat diseases that can be directly related to human life, such as congenital immunodeficiency diseases and hemophilia. Accordingly, SK plasma not only creates economic value, but also creates social value while performing the role of the national health and safety net.
To respond to the rapidly increasing domestic and overseas demand for blood products, SK plasma completed a new, state-of-the-art blood product fractionation plant in Andong, Gyeongsangbuk-do in 2016.
In August 2018, it received KGMP approval and started commercial production. In addition, we are taking the lead in strengthening our competitiveness and improving human health through continuous development of new products.
Address
: 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Tel
: 82-80-969-9967
Homepage
: https://www.skplasma.com